The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 12, 2017

Filed:

Jul. 08, 2016
Applicants:

Abbvie S.à.r.l., Luxembourg, LU;

Galapagos NV, Mechelen, BE;

Inventors:

Robert J. Altenbach, Chicago, IL (US);

Andrew Bogdan, Evanston, IL (US);

Marlon D. Cowart, Round Lake Beach, IL (US);

William Ramesh Esmieu, Saffron Walden, GB;

Gregory A. Gfesser, Lindenhurst, IL (US);

Stephen N. Greszler, Vernon Hills, IL (US);

John R. Koenig, Chicago, IL (US);

Philip R. Kym, Libertyville, IL (US);

Bo Liu, Waukegan, IL (US);

Karine Fabienne Malagu, Saffron Walden, GB;

Sachin V. Patel, Round Lake, IL (US);

Marc J. Scanio, Libertyville, IL (US);

Xenia B. Searle, Grayslake, IL (US);

Eric Voight, Pleasant Prairie, WI (US);

Xeuquing Wang, Northbrook, IL (US);

Ming C. Yeung, Grayslake, IL (US);

Assignees:

AbbVie S.á.r.l., Luxembourg, LU;

Galapagos NV, Mechelen, BE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 493/04 (2006.01); C07D 317/70 (2006.01); C07D 405/12 (2006.01); C07D 407/12 (2006.01); C07D 519/00 (2006.01); A61K 31/357 (2006.01); A61K 31/397 (2006.01); A61K 31/433 (2006.01); A61K 31/443 (2006.01); A61K 31/4439 (2006.01); A61K 31/4709 (2006.01); A61K 31/501 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 493/04 (2013.01); A61K 31/357 (2013.01); A61K 31/397 (2013.01); A61K 31/433 (2013.01); A61K 31/443 (2013.01); A61K 31/4439 (2013.01); A61K 31/4709 (2013.01); A61K 31/501 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 317/70 (2013.01); C07D 405/12 (2013.01); C07D 407/12 (2013.01); C07D 519/00 (2013.01);
Abstract

The present invention provides for compounds of formula (I) wherein X, Y, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).


Find Patent Forward Citations

Loading…